Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $40.70.

Several equities research analysts have issued reports on GMAB shares. Wall Street Zen downgraded shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Truist Financial reaffirmed a “buy” rating and set a $48.00 price target (down from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Morgan Stanley assumed coverage on Genmab A/S in a report on Monday, February 16th. They issued an “equal weight” rating and a $34.00 price target for the company. Guggenheim reduced their price objective on Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Jefferies Financial Group started coverage on Genmab A/S in a research note on Tuesday, February 17th. They issued a “buy” rating and a $41.50 target price for the company.

Institutional Trading of Genmab A/S

A number of hedge funds have recently made changes to their positions in GMAB. DGS Capital Management LLC lifted its position in shares of Genmab A/S by 116.5% during the fourth quarter. DGS Capital Management LLC now owns 18,203 shares of the company’s stock worth $561,000 after purchasing an additional 9,795 shares in the last quarter. Virtu Financial LLC purchased a new stake in Genmab A/S during the 4th quarter worth $697,000. Dorsey Wright & Associates acquired a new position in Genmab A/S in the 4th quarter worth $1,381,000. Corient Private Wealth LLC boosted its position in Genmab A/S by 10.9% in the 4th quarter. Corient Private Wealth LLC now owns 17,469 shares of the company’s stock valued at $535,000 after buying an additional 1,724 shares during the last quarter. Finally, Braeburn Wealth Management LLC acquired a new stake in shares of Genmab A/S during the fourth quarter valued at about $1,084,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Performance

Genmab A/S stock opened at $29.40 on Wednesday. The company has a market cap of $18.89 billion, a price-to-earnings ratio of 18.97, a price-to-earnings-growth ratio of 0.95 and a beta of 0.90. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $35.43. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. The stock’s 50-day moving average is $32.06 and its 200-day moving average is $30.13.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.The firm had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Equities analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.